Illumina shares up on higher sales of gene-sequencing products
April 22 (Reuters) - Life-science tool maker Illumina Inc reported a better-than-expected jump in quarterly revenue, helped by strong sales of its gene-sequencing products.
The company's shares rose about 8.5 percent in after-market trading.
The company's net income rose to $60 million, or 40 cents per share, in the first quarter ended March 31, from a loss of $22.6 million, or 18 cents per share, a year earlier.
Illumina's adjusted profit was 53 cents per share for the quarter.
Revenue rose 27 percent to $420.8 million.
Analysts on average were expecting earnings of 44 cents per share on revenue of $391.8 million, according to Thomson Reuters I/B/E/S. (Reporting By Anjalirao Koppala; Editing by Simon Jennings)
- Israel pummels Gaza; Kerry steps up diplomatic push |
- Ukraine war crimes trials a step closer after Red Cross assessment
- With sales sputtering, Apple's iPad looks to IBM alliance
- Five held in China food scandal probe, including head of Shanghai Husi Food
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand